Celltrion: Major Management Disclosure: Approval of amended Phase 3 clinical trial plan for CTP44 (Darzalex biosimilar) in Korea
AI reading
★★★ Bullish · Material event
Darzalex biosimilar Korea Phase 3 clinical trial amendment approval
Key figures: 394 clinical trial participants, 2-year duration
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Celltrion
- 09.23 ★★★ Zymfentra US Phase 3 clinical trial approval (rheumatoid arthritis)
- 09.23 ★★ Large Shareholding Report (General)
- 09.21 ★★★ Darzalex biosimilar EU Phase 3 clinical trial approval
- 09.16 ★★ Cancellation of treasury shares for stock price stabilization and shareholder value enhancement
- 09.07 ★★★ Keytruda biosimilar US Phase 3 clinical trial amendment approval
- 08.31 ★★★★ Plan for share buyback and full cancellation to stabilize stock price and enhance shareholder value
For information only. Not investment advice.